Proactive Investors - Run By Investors For Investors

SCYNEXIS reveals positive interim data from its Phase 3 FURI study

SCYNEXIS, Inc. (NASDAQ:SCYX) President & CEO Dr. Marco Taglietti sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biotechnology company's lead product candidate is ibrexafungerp (formerly known as SCY-078), an IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections

 
View full SCYX profile View Profile

SCYNEXIS, Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use